Finally, considering the more frequent use of novel agents and antibodies in MM and lymphoma, now and in the future, it is necessary to improve the efficiency of stem cell mobilization, reducing days of leukapheresis and targeting CD34+ collected with cost-effective agents. The gene discussed is CD34; the disease is Miyoshi myopathy.